NASDAQ:VYGR Voyager Therapeutics Q3 2026 Earnings Date & Estimates $1.90 -0.16 (-7.77%) Closing price 10/16/2026 04:00 PM EasternExtended Trading$1.90 0.00 (-0.26%) As of 10/16/2026 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Voyager Therapeutics is estimated to report Q3 2026 earnings on Monday, November 9, 2026. The conference call is scheduled for November 6, 2026 at 4:00 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 9, 2026Conference Call DateNovember 6, 2026Conference Call4:00 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Voyager Therapeutics in Q3 2026Voyager Therapeutics is expected to post earnings of -$0.41 per share on revenue of $6.35 million. In the same quarter a year earlier Voyager Therapeutics reported -$0.47 per share on revenue of $11.15 million. Voyager Therapeutics last reported on August 6, 2026, posting -$0.40 per share and beating the -$0.4838 consensus estimate. Voyager Therapeutics has beaten the consensus EPS estimate in 5 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.41Expected Revenue$6.35 millionPrior-Year EPS-$0.47Prior-Year Revenue$11.15 millionExpected Revenue Growth-43.1%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.40 (Beat by +$0.0838)Last Quarter Revenue$3.17 millionEPS Beat Rate5 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Voyager Therapeutics Q3 2026 Earnings FAQ When does Voyager Therapeutics report Q3 2026 earnings? Voyager Therapeutics (NASDAQ:VYGR) is estimated to report Q3 2026 earnings on Monday, November 9, 2026. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Voyager Therapeutics' Q3 2026 earnings call? Voyager Therapeutics' Q3 2026 earnings conference call is scheduled for Friday, November 6, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Voyager Therapeutics? Analysts expect Voyager Therapeutics to post earnings of -$0.41 per share for Q3 2026. How much revenue is Voyager Therapeutics expected to report? The consensus revenue estimate for Voyager Therapeutics is $6.35 million for Q3 2026. Voyager Therapeutics Earnings HeadlinesVoyager Therapeutics, Inc. (VYGR) Presents at Wells Fargo 21st Annual Healthcare Conference TranscriptSeptember 10, 2026 | seekingalpha.comVoyager to Present at Upcoming Investor ConferencesSeptember 1, 2026 | globenewswire.comYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.October 17 at 1:00 AM | Profits Run (Ad)TD Cowen Remains a Buy on Voyager Therapeutics (VYGR)August 24, 2026 | theglobeandmail.comVoyager Reports Second Quarter 2026 Financial and Operating ResultsAugust 6, 2026 | finance.yahoo.comVoyager Therapeutics (VYGR) Receives a Rating Update from a Top AnalystAugust 4, 2026 | theglobeandmail.comSee More Voyager Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Voyager Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Voyager Therapeutics and other key companies, straight to your email. Email Address About Voyager TherapeuticsVoyager Therapeutics (NASDAQ:VYGR) is a biotechnology company focused on developing gene therapies for neurological diseases. The company uses its proprietary TRACER capsid discovery platform to identify adeno-associated virus (AAV) capsids designed to improve the delivery of genetic medicines to the brain and central nervous system. Voyager’s research and development programs have addressed conditions including Parkinson’s disease, Huntington’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis and Friedreich’s ataxia. Its pipeline has included therapies intended to replace or modify genes, reduce the production of disease-associated proteins, or deliver therapeutic antibodies and other biological payloads to the central nervous system. Founded in 2014 and headquartered in Cambridge, Massachusetts, Voyager has pursued collaborations and licensing arrangements with larger pharmaceutical companies to advance selected gene-therapy programs and apply its capsid technology across additional neurological targets. The company is led by Alfred Sandrock, M.D., Ph.D., who became chief executive officer in 2023 after holding senior research and development positions in the biotechnology industry.View Voyager Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/12 - 10/16Bank of America Stock Sell-Off Looks Like a Buying OpportunityManpowerGroup Stock Sinks on Q3 Results, But Fundamentals Stay SolidMorgan Stanley Beats on Earnings, But Shares Fall on Trading MixFundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out?Palantir's Potential Next Catalyst After Retail Profit-TakingApple Cut iPhone 18 Orders; What Does It Mean For Suppliers? Upcoming Earnings America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026)GE Aerospace (10/20/2026)3M (10/20/2026)Northrop Grumman (10/20/2026)RTX (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
